ADDISON, Texas, Nov. 10, 2010 /PRNewswire/ -- ULURU Inc. (NYSE Amex: ULU) today provided a clinical update and summary of recent participation at major wound care conferences.
During the past 45 days Altrazeal® has been presented at three major wound care conferencesSymposium of Advanced Wound Care ("SAWC") Clinical Symposium on Advances in Skin and Wound Care ("CSASWC") Diabetic Limb Salvage 2010 ("DLS")
Participation in these conferences not only benefit our United States sales and marketing activities but also our expansion into international markets. This is of particular importance given that Altrazeal® was recently granted CE Mark approval, which opens potential pathways for commercialization in 27 European countries and other international markets. The expansion of the clinical evidence supporting Altrazeal® places the Company in a strong position to make major headway in the commercialization of Altrazeal® in the target markets.
At the SAWC and CSASWC out of the hundreds of scientific and clinical poster presentations one in ten featured Altrazeal® or Altrazeal® in combination with other products. Of major significance was the number of posters where wound care professionals are using the properties of Altrazeal® to enhance the benefits or improve the performance of other products. At CSASWC there were 8 posters that presented Altrazeal® in combination with 7 different products. Of these presentations, numerous posters featured Altrazeal® securing skin substitutes and managing wound exudate to enhance the performance of these expensive products.
In addition to the poster presentations Altrazeal® was featured at two workshops at CSASWC. Dr. Greg Bohn demonstrated application techniques for numerous chronic wound types in a wound care simulation workshop. Thi